RXST Earnings & Financial Statements
RxSight, Inc.
$4.52
-$0.01(-0.22%)
48
Overall
60
Value
36
Tech
50
Quality
Market Cap
$188.00M
Volume
826.69K
52W Range
$4.48 - $13.22
Target Price
$7.57
RXST earnings and financial statements: RxSight, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RXST Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $134.48M | $139.93M | $89.08M | $49.01M | $22.59M |
| Cost of revenue | $31.47M | $40.98M | $35.31M | $27.68M | $18.08M |
| Operating income | -$48.20M | -$36.90M | -$50.09M | -$63.32M | -$52.79M |
| EBITDA | -$35.59M | -$23.81M | -$40.75M | -$57.23M | -$40.55M |
| Net income | -$38.94M | -$27.45M | -$48.61M | -$66.76M | -$48.69M |
| EPS (diluted) | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $311.81M | $318.56M | $182.55M | $150.16M | $192.72M |
| Total liabilities | $36.13M | $37.33M | $22.19M | $60.26M | $54.48M |
| Shareholders’ equity | $275.68M | $281.24M | $160.36M | $89.90M | $138.24M |
| Cash and equivalents | $19.95M | $16.71M | $9.69M | $11.83M | $24.36M |
| Long-term debt | - | $11.32M | - | $40.17M | $39.76M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$15.51M | -$16.95M | -$41.59M | -$58.85M | -$44.71M |
| Capital expenditure | -$3.83M | -$5.44M | -$4.81M | -$2.39M | -$1.94M |
| Free cash flow | -$19.34M | -$22.39M | -$46.41M | -$61.24M | -$46.65M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RXST | $4.52 | -0.2% | 826.69K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |